“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock
This article was originally published in The Rose Sheet
Executive Summary
Janet Woodcock says FDA expected when the process was launched to complete all monographs by the year 2000, but 25 remain in tentative final monograph status, with a rulemaking required to finalize each one. “The rulemaking process … doesn’t work for getting monographs done in a very timely manner,” she says.
You may also be interested in...
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.